Startups, Diagnostics

Cancer diagnostics maker Cynvenio Biosystems raises $25.5M

The company’s been positioning itself as a contender in the precision medicine game – helping physicians navigate cancer therapy by examining cancer biomarkers in blood.

Los Angeles cancer diagnostics maker Cynvenio Biosystems just raised $25.5 million, according to a regulatory filing.

The company’s been positioning itself as a contender in the precision medicine game – helping physicians navigate cancer therapy by examining cancer biomarkers in blood.

Cynvenio is known best for its LiquidBiopsy test. It’s a platform that uses a standard blood draw, rather than a tissue biopsy, to learn which genetic mutations are or aren’t present – and help gauge what kind of cancer a patient may have.

To provide cancer diagnostics, it extracts and isolates circulating tumor cells from the blood, then performs high throughput genomic analysis – a project it’s actually working on with Thermo Fisher Scientific.

The funding will be used as working capital for the company, the filing said.